title: Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
abstract: The strategy of World Health Organization is to develop efficient and inexpensive vaccine against various infectious diseases amongst children's population. Vaccination is considered as the most cost effective health intervention known to public. Since 90 years various substances have been added in vaccine formulation but still alum is considered as the safest adjuvant for human use licensed by United States Food and Drug Administration. MF 59 and ASO4 are the adjuvants were developed recently and approved for human use. Due to poor adjuvancity, conventional vaccines require multiple recall injection at approximately time intervals to attain optimal immune response. For past approximately two decades the vaccine research has been focused towards the alternation of alum type of adjuvant in order to increase the immunogenicity. The development of new vaccines, is more efficacious or easier to deliver, or both have become an area of research that can certainly benefit from controlled release technology. Especially, the conversion of multiple administration vaccine into single administration vaccine may represent an improved advancement towards the betterment of human health care and welfare. Biodegradable polymer microparticles have been evaluated for delivering antigens in native form, sustained release keeping in mind the safety aspects. In this article we review the overall concept of adjuvants in vaccine technology with special focus towards the prospects of controlled release antigens.
authors: Unit of Neuroscience and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
authors: S M
authors: SM
authors: Sivakumar
authors: Mohammed M
authors: MM
authors: Safhi
authors: M
authors: M
authors: Kannadasan
authors: N
authors: N
authors: Sukumaran
keywords: Adjuvant and its types; Biodegradable polymers; Immune response; Microparticles; Vaccine delivery
references: Vaccine. 1997 Aug;15(11):1209-13
references: 9286045
references: Proc Soc Exp Biol Med. 1973 Sep;143(4):1053-6
references: 4743681
references: J Exp Med. 1988 Feb 1;167(2):700-5
references: 3279156
references: Adv Vet Sci Comp Med. 1990;35:121-60
references: 2126667
references: Vaccine. 1995 Dec;13(18):1741-9
references: 8701587
references: Vaccine. 1991 Jun;9(6):408-15
references: 1887671
references: Trends Biotechnol. 1999 Jan;17(1):25-9
references: 10098275
references: Eur J Biochem. 2000 Jul;267(13):3946-56
references: 10866793
references: Nature. 1984 Mar 29-Apr 4;308(5958):457-60
references: 6709052
references: AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):1011-20
references: 10445813
references: J Bone Joint Surg Br. 1992 Nov;74(6):853-7
references: 1447246
references: Nature. 1974 Nov 15;252(5480):252
references: 4424229
references: J Immunol. 1948 Nov;60(3):383-98
references: 18890196
references: Vaccine. 2006 Apr 12;24 Suppl 2:S2-7-10
references: 16823907
references: Nat Immunol. 2004 Oct;5(10):971-4
references: 15454919
references: Nature. 1990 Apr 26;344(6269):873-5
references: 2184369
references: Rev Infect Dis. 1980 May-Jun;2(3):370-83
references: 6997966
references: Int J Pharm. 2005 Nov 4;304(1-2):29-39
references: 16181753
references: Int J Pharm. 1999 Aug 20;185(2):255-66
references: 10460920
references: Immunol Rev. 1997 Apr;156:199-209
references: 9176709
references: Vaccine. 2006 Jun 29;24(26):5481-90
references: 16730104
references: Semin Immunol. 2000 Jun;12(3):163-71; discussion 257-344
references: 10910735
references: Biomaterials. 1995 May;16(8):593-9
references: 7548609
references: Vaccine. 2000 Feb 14;18(15):1436-47
references: 10618541
references: J Leukoc Biol. 1998 Dec;64(6):713-23
references: 9850152
references: Vaccine. 2006 Jun 29;24(26):5406-12
references: 16621190
references: Nat Med. 1995 Jul;1(7):649-53
references: 7585145
references: Curr Top Microbiol Immunol. 2009;333:43-82
references: 19768400
references: Dev Biol Stand. 1986;65:131-6
references: 3549396
references: Crit Rev Ther Drug Carrier Syst. 1996;13(1-2):1-55
references: 8853958
references: Hum Vaccin. 2008 Sep-Oct;4(5):347-9
references: 18682690
references: J Control Release. 2006 May 1;112(1):35-42
references: 16516999
references: Ann Emerg Med. 1995 Mar;25(3):328-30
references: 7864471
references: Immunol Today. 1993 Jun;14(6):281-4
references: 8104409
references: Vaccine. 1993;11(3):293-306
references: 8447157
references: Vaccine. 1996 Nov;14(16):1523-30
references: 9014294
references: J Immunol. 1977 Jan;118(1):334-41
references: 830756
references: Jpn J Pharmacol. 2000 Mar;82(3):218-25
references: 10887952
references: Int J Pharm. 2006 Jan 3;307(1):93-102
references: 16303268
references: Clin Pharmacol Ther. 2007 Dec;82(6):740-4
references: 17971820
references: Vaccine. 1994 Apr;12(5):387-400
references: 8023545
references: Int J Pharm. 2004 Apr 15;274(1-2):1-33
references: 15072779
references: Nat Med. 2005 Apr;11(4 Suppl):S63-8
references: 15812492
references: J Pharm Sci. 1996 Jun;85(6):547-52
references: 8773947
references: Int J Pharm. 2007 Feb 1;329(1-2):142-9
references: 17000065
references: J Immunol Methods. 1979;28(1-2):193-7
references: 469267
references: Immunity. 1998 Jan;8(1):89-95
references: 9462514
references: Ann Allergy. 1968 Jun;26(6):288-92
references: 4968382
references: Expert Rev Vaccines. 2002 Jun;1(1):111-8
references: 12908518
references: Vaccine. 1995 May;13(7):683-9
references: 7668038
references: Ann Allergy. 1972 Mar;30(3):146-51
references: 4622115
references: Ann Allergy. 1985 Jun;54(6):521-9
references: 4014780
references: Cell. 2006 Feb 24;124(4):783-801
references: 16497588
references: Mol Biother. 1989;1(6):290-6
references: 2692629
references: J Immunol. 1996 May 15;156(10):3721-6
references: 8621907
references: Adv Drug Deliv Rev. 1997 Oct 13;28(1):97-119
references: 10837567
references: Mol Biother. 1991 Mar;3(1):41-5
references: 1648929
references: Immunol Cell Biol. 2004 Oct;82(5):488-96
references: 15479434
references: Vaccine. 1992;10(2):75-88
references: 1539467
references: Vaccine. 2002 May 31;20 Suppl 3:S18-23
references: 12184360
references: Immunology. 1983 May;49(1):37-44
references: 6341213
references: Nat Immunol. 2006 May;7(5):449-55
references: 16622432
references: Science. 1977 Mar 4;195(4281):834-47
references: 320661
references: Vaccine. 2007 May 10;25(19):3752-62
references: 17336431
references: Nature. 1962 Mar 17;193:1086-7
references: 14488296
references: Biochem Soc Trans. 1976;4(1):129-33
references: 1001617
references: Vaccine. 2002 May 31;20 Suppl 3:S24-33
references: 12184361
references: Vaccine. 1991 May;9(5):351-7
references: 1872020
references: Mol Immunol. 1991 Mar;28(3):279-84
references: 1850114
references: Pharm Biotechnol. 1995;6:525-41
references: 7551234
references: Proc Soc Exp Biol Med. 1977 Dec;156(3):431-5
references: 304215
references: Eur J Surg. 1993 May;159(5):301-5
references: 8103365
references: Vaccine. 2003 Mar 28;21(13-14):1400-8
references: 12615436
references: J Microbiol Immunol Infect. 2010 Aug;43(4):265-70
references: 20688285
references: Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4942-6
references: 8506338
references: Biochim Biophys Acta. 1976 Dec 14;457(3-4):259-302
references: 793635
references: Scand J Infect Dis. 2002;34(8):610-4
references: 12238579
references: Bibl Tuberc. 1956;(10):130-48
references: 13341884
references: Vaccine. 1998 Nov;16 Suppl:S104-8
references: 9915049
references: Methods Enzymol. 1983;93:83-95
references: 6346015
references: Adv Drug Deliv Rev. 2002 Oct 4;54(6):863-70
references: 12363435
references: Vaccine. 2006 Mar 20;24(13):2238-47
references: 16455165
references: Ann Allergy. 1972 Aug;30(8):477-83
references: 5044500